N. Ghinea

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
N. Ghinea, Narcyz Ghinea
Publication record
71 papers · 385 citations · H-index 12

PAPERS

Environmental considerations in human genomic data governance: overcoming normative challenges.
20260 citationsauthor #1
Effectiveness of a virtual hospital model of care for patients with low back pain presenting to emergency departments (Back@Home)
20260 citationsauthor #24
Patient‐driven personal importation in the face of cost barriers to care: can we do better?
20250 citationsauthor #1
Should Australian laws regulating embryo research be reformed? A call for commonwealth review.
20250 citationsauthor #1
Why Stop at a Right to Notice for AI Systems Used in Patient Care? The Need for Greater Specificity
20250 citationsauthor #1
How Can the Law Keep Up? The Challenges in Regulating Health Innovations through the Lens of Embryo Research.
20250 citationsauthor #4
A physician’s identity can never be reconfigured to put climate protection on par with an individual patient’s best interests
20242 citationsauthor #1
An Analysis of Australia’s Legal Framework for Access to More Affordable but Unapproved Medicines and Biologics
20241 citationsauthor #1
The Medicines Repurposing Program - a critical perspective.
20243 citationsauthor #1
Cost barriers to medication access in Australia: an analysis of the Patient Experience Survey in context
20242 citationsauthor #1
The increasing costs of medicines and their implications for patients, physicians and the health system
20248 citationsauthor #1
Cost-Related Non-Adherence to Prescribed Medicines: What Are Physicians’ Moral Duties?
20249 citationsauthor #1
Aligning legislation with clinical practice: off‐label prescribing under the microscope
20240 citationsauthor #1
Do Doctors Have a Responsibility to Challenge the Distorting Influence of Commerce on Healthcare Delivery? The Case of Assisted Reproductive Technology
20240 citationsauthor #4
Promoting the personal importation of therapeutic goods: recent legislative amendments to advertising regulations may impact consumer access and understanding.
20232 citationsauthor #2
Physicians' legal duty to disclose more cost-effective treatment options: an examination of Australian civil law applied to personal importation.
20232 citationsauthor #1
Clinicians’ Perspective on Implementing Virtual Hospital Care for Low Back Pain: Qualitative Study
20235 citationsauthor #9
What about the reasonableness of patients’ risk attitudes? A challenge to Makins’ antipaternalistic account
20231 citationsauthor #1
The incidence of personal importation of prescription medicines among Australians 45 and older: a cross-sectional survey.
20233 citationsauthor #1
‘First ensure no regret’: a decision-theoretic approach to informed consent in clinical practice
20234 citationsauthor #1
How therapeutic advances have transformed the medical landscape: a primer for clinicians
20231 citationsauthor #1
Do doctors have a responsibility to help patients import medicines from abroad?
20223 citationsauthor #1
Situating commercialization of assisted reproduction in its socio-political context: a critical interpretive synthesis
20228 citationsauthor #1
Personal Importation and the Law: Protecting Patients Who Import Medicines for Legitimate Health Care Needs.
20223 citationsauthor #1
Ethics Consultation Services as a Resource and its Implications for Evaluation Activities
20220 citationsauthor #1
Regulating autologous stem cell interventions in Australia: updated review of the direct-to-consumer advertising restrictions.
20212 citationsauthor #2
The Oversight of Clinical Innovation in a Medical Marketplace
20211 citationsauthor #3
Consumer perspectives of accelerated access to medicines: a qualitative study.
20214 citationsauthor #2
A return to reasonableness and virtue in medical epistemology.
20204 citationsauthor #1
"Some sort of fantasy land": A qualitative investigation of appropriate prescribing in cancer care.
20201 citationsauthor #1
A survey of Australian public attitudes towards funding of high cost cancer medicines.
20205 citationsauthor #1
Unconventional Practice, "Innovative" Interventions and the National Law.
20201 citationsauthor #8
Emergency department care for low back pain: Should we adopt recommendations from primary care guidelines?
202012 citationsauthor #2
Australian regulation of autologous human cell and tissue products: implications for commercial stem cell clinics.
20206 citationsauthor #1
Lead Essay: Money, Equity and Access to Medicines
20202 citationsauthor #1
Death, dying and donation: community perceptions of brain death and their relationship to decisions regarding withdrawal of vital organ support and organ donation
202012 citationsauthor #6
Does Consumer Engagement in Health Technology Assessment Enhance or Undermine Equity?
20204 citationsauthor #1
Are my religious beliefs anyone’s business? A framework for declarations in health and biomedicine
20202 citationsauthor #1
Citizen Science and the Politicization of Epistemology
20196 citationsauthor #1
Clarifying the Relationship Between Serious Ethical Violations and Conflicts of Interest
20195 citationsauthor #2
Clearing the air: towards agreement about access to high cost cancer medicines.
20196 citationsauthor #4
Is it ethical to prescribe paracetamol for acute low back pain and osteoarthritis?
20191 citationsauthor #4
Limiting religious contributions - a response to Schuklenk.
20191 citationsauthor #2
'Treat them into the grave': cancer physicians' attitudes towards the use of high-cost cancer medicines at the end of life.
201815 citationsauthor #2
An ethical framework for the creation, governance and evaluation of accelerated access programs.
201813 citationsauthor #2
Clinical Quandaries Associated With Accelerated Access to Medicines
20181 citationsauthor #2
Off-Label Prescribing
20180 citationsauthor #1
Faster access to new drugs doesn’t always mean better treatment
20170 citationsauthor #1
The complex legal and ethical issues related to generic medications. Viral hepatitis: a case study
20177 citationsauthor #3
Caution needed in introduction of provisional approvals for medicines
20171 citationsauthor #2
Access to High Cost Cancer Medicines Through the Lens of an Australian Senate Inquiry—Defining the “Goods” at Stake
20178 citationsauthor #1
Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries.
201737 citationsauthor #1
The Right to Health: Implications for the Funding of Medicines in Australia.
20171 citationsauthor #2
Demands for access to new therapies: are there alternatives to accelerated access?
201718 citationsauthor #2
Challenges to the validity of using medicine labels to categorize clinical behavior: An empirical and normative critique of “off‐label” prescribing
201713 citationsauthor #1
Accelerated Access to Medicines: An Ethical Analysis
201714 citationsauthor #2
Importation of generic hepatitis C therapies: Bridging the price - access gap in high-income countries
20162 citationsauthor #1
CommInsure scandal reminds us commercial forces are at play in medicine
20160 citationsauthor #3
Propaganda or the cost of innovation? Challenging the high price of new drugs
201621 citationsauthor #1
Affordable access to innovative cancer medicines — don't forget the prices
20166 citationsauthor #1
NEGOTIATING LIMITS TO THE FUNDING OF HIGH COST CANCER MEDICINES
20162 citationsauthor #2
Evidence, regulation and 'rational' prescribing: the case of gabapentin for neuropathic pain.
201523 citationsauthor #1
Propaganda or cost of innovation? The high price of new drugs
20150 citationsauthor #1
If we don’t talk about value, cancer drugs will become terminal for health systems
201524 citationsauthor #1
x?
20151 citationsauthor #1
The Ethics Around Drug Labels and Generic Medicines
20151 citationsauthor #3
Overcoming entrenched disagreements: the case of misoprostol for post-partum haemorrhage.
20158 citationsauthor #1
Ethics & evidence in medical debates: the case of recombinant activated factor VII.
20146 citationsauthor #1
No evidence or no alternative? Taking responsibility for off‐label prescribing
201214 citationsauthor #1
Estimating the annual rate of de novo multiple aneurysms: three statistical approaches.
200412 citationsauthor #2
A probabilistic and interactive decision-analysis system for unruptured intracranial aneurysms.
20046 citationsauthor #1

TIMELINE

2004 18 citations

2012 14 citations

2014 6 citations

2015 57 citations

2016 31 citations

2017 99 citations

2018 29 citations

2019 19 citations

2020 49 citations

2021 7 citations

2022 14 citations

2023 18 citations

2024 25 citations

2025 0 citations

2026 0 citations

COAUTHOR MAP

CONCEPT FOOTPRINT